Do you want to read an article? Please log in or register.
PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
RECOMMENDED
Related content
Cardiovascular Risk and DiseasesHeart FailureMyocardial InfarctionThrombosis and Stroke
Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
Circulation.
Mahaffey KW, Neal B, Perkovic V, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Fabbrini E, Sun T, Li Q, Desai M, Matthews DR; CANVAS Program Collaborative Group
doi: 10.1161/CIRCULATIONAHA.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Cardiovascular Risk and Diseases
The rise and fall of aspirin in the primary prevention of cardiovascular disease
Lancet.
Raber I, McCarthy CP, Vaduganathan M, Bhatt DL, Wood DA, Cleland JGF, Blumenthal RS, McEvoy JW
doi: 10.1016/S0140-6736(19)30541-0.
Cardiovascular Risk and Diseases
Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial
Lancet.
Roshandel G, Khoshnia M, Poustchi H, Hemming K, Kamangar F, Gharavi A, Ostovaneh MR, Nateghi A, Majed M, Navabakhsh B, Merat S, Pourshams A, Nalini M, Malekzadeh F, Sadeghi M, Mohammadifard N, Sarrafzadegan N, Naemi-Tabiei M, Fazel A, Brennan P, Etemadi A, Boffetta P, Thomas N, Marshall T, Cheng KK, Malekzadeh R
doi: 10.1016/S0140-6736(19)31791-X.
RECOMMENDED
Cardiovascular Risk and DiseasesHeart, Artery and Coronary Diseases
Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc
Ambrosy AP, Yang J, Sung SH, Allen AR, Fitzpatrick JK, Rana JS, Wagner J, Philip S, Abrahamson D, Granowitz C, Go AS
doi: 10.1161/JAHA.120.020377
Heart, Artery and Coronary Diseases
Eligibility and Preventive Potential for New Evidence-Based Cardiovascular Drugs in Secondary Prevention
JAMA Cardiol.
Mortensen MB, Blaha MJ, Nordestgaard BG
doi: 10.1001/jamacardio.2019.4759.
Cardiovascular Risk and Diseases
Omega-3 Polyunsaturated Fatty Acid (Fish Oil) Supplementation and the Prevention of Clinical Cardiovascular Disease: A Science Advisory From the American Heart Association
Circulation.
Siscovick DS, Barringer TA, Fretts AM, Wu JH, Lichtenstein AH, Costello RB, Kris-Etherton PM, Jacobson TA, Engler MB, Alger HM, Appel LJ, Mozaffarian D; American Heart Association Nutrition Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology
doi: 10.1161/CIR.
RECOMMENDED
Cardiovascular Risk and Diseases
Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)
Eur Heart J Acute Cardiovasc Care.
Rossello X, Dorresteijn JA, Janssen A, Lambrinou E, Scherrenberg M, Bonnefoy-Cudraz E, Cobain M, Piepoli MF, Visseren FL, Dendale P
doi: 10.1177/2048872619858285.
Cardiovascular Risk and Diseases
Primary and Secondary Prevention of Cardiovascular Disease in the Era of the Coronavirus Pandemic
No abstract available